This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
dermatol doi | 32 |
doc id | 32 |
acad dermatol | 32 |
cord uid | 32 |
clinical trials | 15 |
monoclonal antibody | 13 |
contact dermatitis | 13 |
leo pharma | 10 |
plaque psoriasis | 10 |
severe psoriasis | 10 |
mh rd | 9 |
autoimmune diseases | 9 |
jak inhibitors | 9 |
systematic review | 9 |
type i | 9 |
teledermatology visits | 8 |
infectious pneumonia | 8 |
patient safety | 8 |
viral urtis | 8 |
coronavirus disease | 8 |
necrosis factor | 8 |
patients receiving | 8 |
respiratory syndrome | 8 |
protective equipment | 8 |
acute respiratory | 8 |
psoriatic arthritis | 8 |
case series | 8 |
phase iii | 7 |
ischemic lesions | 7 |
psoriatic patients | 7 |
syndrome coronavirus | 7 |
tumor necrosis | 7 |
infectious ild | 7 |
hair loss | 6 |
cutaneous manifestations | 6 |
like exanthem | 6 |
asynchronous teledermatology | 6 |
health care | 6 |
chronic plaque | 6 |
predictive value | 6 |
gabrin sign | 6 |
ace expression | 6 |
clinical trial | 6 |
treatment group | 6 |
androgenetic alopecia | 6 |
controlled trial | 6 |
like lesions | 6 |
positive predictive | 6 |
severe covid | 6 |
increased risk | 6 |
atopic dermatitis | 6 |
healthcare workers | 6 |
prospective cohort | 6 |
severe plaque | 6 |
severe acute | 6 |
hospitalized covid | 6 |
publication bias | 6 |
occupational dermatoses | 5 |
respiratory tract | 5 |
severe baldness | 5 |
lung disease | 5 |
immune response | 5 |
personal protective | 5 |
risk factors | 5 |
i ifn | 5 |
viral infections | 5 |
allergic contact | 5 |
general population | 5 |
patients treated | 5 |
psoriasis efficacy | 5 |
program director | 5 |
away rotations | 5 |
hidradenitis suppurativa | 5 |
viral infection | 5 |
psoriasis patients | 5 |
medical students | 5 |
drugs used | 5 |
case report | 5 |
pandemic date | 5 |
significantly increased | 5 |
dermatology residency | 4 |
active patients | 4 |
classic systemic | 4 |
inflammatory cytokines | 4 |
severe disease | 4 |
human interleukin | 4 |
biologic treatments | 4 |
face masks | 4 |
randomized controlled | 4 |
virtual visits | 4 |
polyethylene glycols | 4 |
randomized clinical | 4 |
trial efficacy | 4 |
japanese patients | 4 |
antibody treatment | 4 |
biologic therapies | 4 |
overall risk | 4 |
american academy | 4 |
biologic agents | 4 |
novel coronavirus | 4 |
livedo reticularis | 4 |
interstitial lung | 4 |
biobadaderm registry | 4 |
viral immune | 4 |
residency application | 4 |
application process | 4 |
receiving adalimumab | 4 |
main analysis | 4 |
pharmaceutical companies | 4 |
dermatology residents | 4 |
hospitalized patients | 4 |
herpes simplex | 4 |
manufacture drugs | 4 |
skin ace | 4 |
potential host | 4 |
base population | 4 |
person visits | 4 |
like rash | 4 |
severe outcomes | 4 |
hospital universitario | 4 |
mg dose | 4 |
control group | 3 |
rectal epithelia | 3 |
associated skin | 3 |
systematic reviews | 3 |
united states | 3 |
dermatology clinic | 3 |
specific programs | 3 |
study suggests | 3 |
phase trials | 3 |
respiratory disease | 3 |
prospective study | 3 |
type psoriasis | 3 |
sexual intercourse | 3 |
surgical procedure | 3 |
dermatology practices | 3 |
residency program | 3 |
specific covid | 3 |
severe respiratory | 3 |
acute acro | 3 |
severe chronic | 3 |
trials sponsored | 3 |
immunomodulators immunosuppressants | 3 |
male pattern | 3 |
tract infections | 3 |
data suggest | 3 |
ifn response | 3 |
current covid | 3 |
growth factor | 3 |
students without | 3 |
transmission routes | 3 |
home dermatology | 3 |
randomized trial | 3 |
worse outcomes | 3 |
hs patients | 3 |
covid toes | 3 |
controlled phase | 3 |
included studies | 3 |
systemic therapies | 3 |
patients seen | 3 |
facial protective | 3 |
disease course | 3 |
epithelial cells | 3 |
required hospitalization | 3 |
immune responses | 3 |
study efficacy | 3 |
based care | 3 |
funnel plot | 3 |
occupational dermatitis | 3 |
skin manifestation | 3 |
i interferon | 3 |
positive patients | 3 |
simplex zoster | 3 |
virtual interviews | 3 |
study include | 3 |
medical face | 3 |
multicenter case | 3 |
phase ii | 3 |
english speaking | 3 |
constant correction | 3 |
concomitant drugs | 3 |
adverse events | 3 |
infection control | 3 |
response may | 3 |
polypropylene degradation | 3 |
associated crs | 3 |
procedure masks | 3 |
brett title | 3 |
controlled trials | 3 |
permitted concomitant | 3 |
cohort study | 3 |
great interest | 3 |
inflammatory diseases | 3 |
director panelists | 3 |
randomly selected | 3 |
medical care | 3 |
potential risk | 3 |
visits conducted | 3 |
early data | 3 |
facial occupational | 2 |
collected information | 2 |
group compared | 2 |
outpatient setting | 2 |
welldefined base | 2 |
mucocutaneous candidiasis | 2 |
yiv rp | 2 |
rare events | 2 |
herpetic lesions | 2 |
janus kinase | 2 |
reverse transcription | 2 |
interpreter service | 2 |
lower risk | 2 |
versus placebo | 2 |
surgical uniforms | 2 |
application cycle | 2 |
retrospective review | 2 |
mg kg | 2 |
ncov acute | 2 |
year results | 2 |
specific study | 2 |
psummit trial | 2 |
polyethylene glycol | 2 |
meet inclusion | 2 |
disease control | 2 |
formaldehyde textile | 2 |
ionic surfactants | 2 |
interleukin monoclonal | 2 |
consensus study | 2 |
prisma statement | 2 |
patients sought | 2 |
analysis revealed | 2 |
universitario dr | 2 |
nationwide consensus | 2 |
based treatment | 2 |
diagnostic accuracy | 2 |
confirmed cases | 2 |
phase clinical | 2 |
cases published | 2 |
spanish ministry | 2 |
dermatology visits | 2 |
dermatology program | 2 |
cases according | 2 |
biologic treatment | 2 |
paper products | 2 |
uk biobank | 2 |
history questionnaires | 2 |
previous co | 2 |
gastrointestinal tract | 2 |
facial masks | 2 |
compare significance | 2 |
ongoing international | 2 |
disease testing | 2 |
hand sanitizer | 2 |
cell transcriptome | 2 |
nasopharyngeal swab | 2 |
cytokine storm | 2 |
controlled study | 2 |
examined hospitalization | 2 |
analysis examined | 2 |
controlled voyage | 2 |
polyoxyethylenic non | 2 |
phase study | 2 |
masks allergic | 2 |
skin disease | 2 |
selection bias | 2 |
current comorbidities | 2 |
one case | 2 |
fatality rate | 2 |
prospective nationwide | 2 |
calcineurin inhibitors | 2 |
vdbk pl | 2 |
week results | 2 |
cytokine activity | 2 |
current active | 2 |
systemic therapy | 2 |
observed cases | 2 |
wall street | 2 |
chemical evaluation | 2 |
study within | 2 |
paid speaker | 2 |
resembling lr | 2 |
health products | 2 |
prospective studies | 2 |
textile masks | 2 |
aap cte | 2 |
statistical analyses | 2 |
spanish medicines | 2 |
irb approval | 2 |
likely suffer | 2 |
epidemiologic studies | 2 |
maintenance therapy | 2 |
high risk | 2 |
significantly higher | 2 |
needed icu | 2 |
sex standardized | 2 |
preferred reporting | 2 |
dermatologic manifestation | 2 |
age groups | 2 |
higher percentages | 2 |
phase trial | 2 |
active comparator | 2 |
biological drugs | 2 |
infectious patients | 2 |
descriptive frequencies | 2 |
hospitalized men | 2 |
robust anti | 2 |
balding patterns | 2 |
molecular confirmations | 2 |
patients due | 2 |
expected number | 2 |
confirmed patients | 2 |
clinical benefit | 2 |
masks autoxidation | 2 |
event studies | 2 |
chronic mucocutaneous | 2 |
combined average | 2 |
abbott abbvie | 2 |
registries based | 2 |
preliminary study | 2 |
dermatologic needs | 2 |
derivatives contact | 2 |
varicella zoster | 2 |
data updated | 2 |
like hypertension | 2 |
iii clinical | 2 |
clinical research | 2 |
sana academia | 2 |
reference center | 2 |
medical advice | 2 |
first perspective | 2 |
front line | 2 |
old caucasian | 2 |
authors consider | 2 |
skin care | 2 |
test scores | 2 |
skin lesions | 2 |
one patient | 2 |
table i | 2 |
oral transmission | 2 |
systemic treatments | 2 |
androgen sensitivity | 2 |
recently published | 2 |
patients infected | 2 |
three patients | 2 |
described national | 2 |
treated patients | 2 |
study safety | 2 |
air exposure | 2 |
rapid prospective | 2 |
identified formaldehyde | 2 |
immunosuppressant use | 2 |
glycols peroxides | 2 |
teledermatology service | 2 |
pattern baldness | 2 |
sexual transmission | 2 |
glycol derivatives | 2 |
international registries | 2 |
infectious diseases | 2 |
risk stratification | 2 |
nan covid | 2 |
may prove | 2 |
hospital outcomes | 2 |
spanish figures | 2 |
may help | 2 |
cutaneous findings | 2 |
acral lesions | 2 |
dr herrera | 2 |
systemic drugs | 2 |
among healthcare | 2 |
histological study | 2 |
patients experiencing | 2 |
patient records | 2 |
nasal bridge | 2 |
receiving biologic | 2 |
concomitant therapies | 2 |
divided rtis | 2 |
multiple sclerosis | 2 |
lpl eo | 2 |
pandemic covid | 2 |
voyage trial | 2 |
advice requests | 2 |
intensive care | 2 |
standard precautions | 2 |
first data | 2 |
mediated inflammatory | 2 |
host response | 2 |
urys ry | 2 |
standardized incidence | 2 |
patient concerns | 2 |
analysis date | 2 |
cell differentiation | 2 |
kg i | 2 |
best suited | 2 |
late manifestation | 2 |
products agency | 2 |
without home | 2 |
insufficient evidence | 2 |
dermatology application | 2 |
severe atopic | 2 |
following companies | 2 |
respirator identified | 2 |
patients may | 2 |
respiratory pathogens | 2 |
comorbidities like | 2 |
healthcare disparities | 2 |
visits also | 2 |
polymerase chain | 2 |
org article | 2 |
cellulitis treatment | 2 |
including acne | 2 |
become infected | 2 |
oral mucosa | 2 |
spanish population | 2 |
collaborating pharmaceutical | 2 |
diabetes mellitus | 2 |
shifting landscape | 2 |
treatments increase | 2 |
adalimumab qw | 2 |
antibody therapy | 2 |
including abbvie | 2 |
microneedle array | 2 |
bqw zi | 2 |
adverse skin | 2 |
international medical | 2 |
fp phk | 2 |
upper respiratory | 2 |
disease severity | 2 |
following use | 2 |
bowel disease | 2 |
medical education | 2 |
pcr tests | 2 |
gallego infections | 2 |
patient died | 2 |
skin status | 2 |
four cases | 2 |
hydroxychloroquine use | 2 |
street journal | 2 |
infections associated | 2 |
local shelters | 2 |
also ci | 2 |
national health | 2 |
financial support | 2 |
lessons learned | 2 |
mild courses | 2 |
inclusion criteria | 2 |
primary objective | 2 |
innovative ways | 2 |
drugs compared | 2 |
including patient | 2 |
experiencing homelessness | 2 |
sun exposure | 2 |
symptoms began | 2 |
latest data | 2 |
also collaborated | 2 |
isgcm lj | 2 |
skin reactions | 2 |
unequal access | 2 |
avoids problems | 2 |
discussing specificity | 2 |
rheumatoid arthritis | 2 |
reporting items | 2 |
acutely infected | 2 |
productos sanitarios | 2 |
patients included | 2 |
patients taking | 2 |
ankylosing spondylitis | 2 |
biobadaderm project | 2 |
adequate denominators | 2 |
glandular cells | 2 |
shared decision | 2 |
study therefore | 2 |
deteriorated barrier | 2 |
observational study | 2 |
inflammatory bowel | 2 |
alopecia present | 2 |
severe aga | 2 |
pulmonary toxicities | 2 |
plasma cells | 2 |
nclk bbo | 2 |
using prospective | 2 |
increase neither | 2 |
performed using | 2 |
public health | 2 |
home care | 2 |
funnel plots | 2 |
disease covid | 2 |
safety results | 2 |
outpatient facilities | 2 |
therefore avoids | 2 |
active psoriatic | 2 |
viral type | 2 |
also known | 2 |
personal statement | 2 |
neck surgery | 2 |
ill patients | 2 |
extensive debate | 2 |
piel sana | 2 |
patient characteristics | 2 |
medical center | 2 |
dr kansal | 2 |
incidence ratio | 2 |
nonwoven textile | 2 |
chain reaction | 2 |
confidence interval | 2 |
nuclear factor | 2 |
widely used | 2 |
fda approved | 2 |
dermatology applicants | 2 |
allergenic activity | 2 |
contact allergenic | 2 |
biobadaderm patient | 2 |
previously described | 2 |
textile resins | 2 |
receives financial | 2 |
viral clearance | 2 |
small molecule | 2 |
healthy subjects | 2 |
qd xdr | 2 |
prolonged wear | 2 |
case notifications | 2 |
immunomodulator immunosuppressant | 2 |
prove useful | 2 |
ed physicians | 2 |
aq vius | 2 |
facial contact | 2 |
possible cases | 2 |
descalzo gallego | 2 |
medical school | 2 |
care companies | 2 |
sensitivity analysis | 2 |
clinical presentation | 2 |
trial ustekinumab | 2 |
comorbidities related | 2 |
may continue | 2 |
dermatology programs | 2 |